Navigation Links
Alexza Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Date:3/1/2010

MOUNTAIN VIEW, Calif., March 1 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company Senior Vice President and CFO August J. Moretti will present during the Cowen and Company 30th Annual Health Care Conference on Tuesday, March 9, 2010 at 3:00 p.m. ET.  The presentation will be webcast from the Marriott Copley Place Hotel in Boston, MA.

To access the presentation via the Web, please go to the Investor Relations tab at www.alexza.com or at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ALXA&item_id=2780036.  A replay of the webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.  

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application submission in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.    

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.  

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial.  Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia.  More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission.  Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.alexza.com

'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Alexza to Announce 2009 Year-End Financial Results on Monday, March 8, 2010
2. Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
3. Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
4. A Random Act of Kindness Changes a Familys Life Forever as Alexzander Prados Wish to Walk is Granted at Abilities Expo
5. Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
6. Alexzas Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
7. Alexzas Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference
8. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
9. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
10. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
11. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location dental ... offering laser dental treatments. Dental lasers are safe and effective options, and can be ... and can improve the overall quality of care. , Dr. Hamid Reza of Hamlin ...
(Date:3/29/2017)... Richmond, VA (PRWEB) , ... March 29, 2017 , ... ... of its seventh North American office location in Richmond, Virginia, located at the Riverfront ... April 11, attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as it ... either don’t have access to a health care facility or a pharmacy within 60 minutes ... the United States or for many who are faced with health or personal issues that ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... elected representatives in state legislatures and Congress to protect parental rights and civil ... health and safety in America. , The demonstration coincides with a press conference ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... FRANCISCO , March 29, 2017  Spiral ... option agreement with Bionure Farma, S.L. for the ... and to BN119 in the field of otolaryngology ... plus sales-based royalties. The agreement provides Spiral ... assets with a differentiated product profile. Under the ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology: